Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04928677 · ClinicalTrials.gov registry record · Phase 1
A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment
A Phase 1 study of Primary Extra-cranial Solid Tumor and Recurrent or Refractory Glypican 3 (GPC3), sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 5
- Study locations
NCT04928677: Recruiting Phase 1 study of Primary Extra-cranial Solid Tumor and Recurrent or Refractory Glypican 3 (GPC3), sponsored by Memorial Sloan Kettering Cancer Center.
NCT04928677 is a Phase 1 study of Primary Extra-cranial Solid Tumor and Recurrent or Refractory Glypican 3 (GPC3) that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 50 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04928677, a Phase 1 study of Primary Extra-cranial Solid Tumor and Recurrent or Refractory Glypican 3 (GPC3), is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study to find out whether codrituzumab is a safe treatment that causes few or mild side effects in children and young adults who have solid tumors that express the protein GPC3. The researchers also want to study the way codrituzumab is absorbed, distributed, and cleared from the body.
Primary Outcome
The Phase A dose escalation scheme will follow a 3+3 design.
Conditions Studied
Interventions
- DRUG Codrituzumab
Study Locations (5)
California
- Children's Hospital of Los Angeles (Data Collection Only) - Los Angeles
Georgia
- Children's Healthcare of Atlanta (Data Collection Only) - Atlanta
Massachusetts
- Dana Farber Cancer Institute (Data Collection Only) - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-06-09 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
What NCT04928677 shows while recruiting
NCT04928677 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% lower).
The record links to 2 conditions, with Primary Extra-cranial Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Codrituzumab is the first listed.
NCT04928677 lists 5 locations in 5 states (California, Georgia, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT04928677 about?
NCT04928677 is a clinical study titled "A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment". The purpose of this study to find out whether codrituzumab is a safe treatment that causes few or mild side effects in children and young adults who have solid tumors that express the protein GPC3. The researchers also want to study the way codrituzumab is absorbed, distributed, and cleared from the...
What is the current status of trial NCT04928677?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2021-06-09. Estimated completion is 2027-06.
What conditions does trial NCT04928677 study?
This clinical trial studies the following conditions: Primary Extra-cranial Solid Tumor, Recurrent or Refractory Glypican 3 (GPC3).
What interventions are being tested in trial NCT04928677?
The interventions under investigation include: Codrituzumab (DRUG).
Who is sponsoring clinical trial NCT04928677?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04928677 being conducted?
This trial has 5 study locations across California, Georgia, Massachusetts, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04928677's enrollment target sits among peer trials
50 973rd of 2000 higher than 984 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI